US4348376A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tumor localization and therapy with labeled anti-CEA antibody
Assignee: Individual
•
Filing: 1980-03-03
•
Granted: 1982-09-07
•
Expires: 2000-03-03
Abstract
Abstract Improved methods are provided for using radiolabeled antibodies to carcinoembronic antigen (CEA) to locate, diagnose and stage CEA-containing tumors by external photoscanning, whereby significantly increased resolution, convenience and/or efficiency of operation may be achieved. A method is provided for using highly specific radiolabeled anti-CEA antibodies for tumor therapy. An injectable composition and radiolabeled antibodies are provided for use in the method of the invention.
Inventors
- 👤 Milton D. Goldenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:24
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3007; A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1045; A61K51/1048; A61K2121/00; A61K2123/00; A61K38/00
Claims Analysis
Total Claims: 47
Claim 1
Independent Claim
174 words
In a method for determining the location of a tumor which either produces or is associated with carcinoembryonic antigen (CEA), which comprises injecting a human subject parenterally with an antibody specific to CEA and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device and subsequently scanning the subject with said device to determine the location of the resultant uptake of said labeled antibody by said tumor; the improvement which comprises concurrently injecting said human subject with normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with a different radioisotope of the same element used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device, the level of activity of the labeled normal immunoglobulin being used to determine the distribution of background activity due to non-targeted specific antibody, said distribution being subtracted from the total activity of specific antibody whereby the activity of substantially only the targeted tumor-associated antibody is determined.
Claim 2
Dependent Claim
174 words
In a method for determining the location of a tumor which either produces or is associated with carcinoembryonic antigen (CEA), which comprises injecting a human subject parenterally with an antibody specific to CEA and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device and subsequently scanning the subject with said device to determine the location of the resultant uptake of said labeled antibody by said tumor; the improvement which comprises concurrently injecting said human subject with normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with a different radioisotope of the same element used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device, the level of activity of the labeled normal immunoglobulin being used to determine the distribution of background activity due to non-targeted specific antibody, said distribution being subtracted from the total activity of specific antibody whereby the activity of substantially only the targeted tumor-associated antibody is determined.
Claim 3
Dependent Claim
41 words
The method of claim 1, wherein the specific anti-CEA antibody is labeled with one of, and the normal immunoglobulin is labled with the other of Iodine-131 and Iodine-123; Indium-111 and Indium-113m; Gallium-67 and Gallium-68; Ruthenium-97 and Ruthenium-103; or Mercury-197 and Mercury-203.
Claim 4
Dependent Claim
31 words
The method of claim 1, wherein the specific anti-CEA antibody is labeled with one of Iodine-131 or Iodine-123 and the normal immunoglobulin is labeled with the other of Iodine-131 or Iodine-123.
Claim 5
Dependent Claim
32 words
The method of claim 1, wherein the amount of radiolabel introduced into the specific anti-CEA antibody is sufficient to reduce the CEA specific immunoreactivity of said antibody by from 5 to 33%.
Claim 6
Dependent Claim
15 words
The method of claim 4, wherein said immunoreactivity is reduced by from 10 to 25%.
Claim 7
Dependent Claim
30 words
The method of claim 4, wherein the specific anti-CEA antibody is radiolabeled with Iodine-131 or Iodine-123, an average of at least 2.5 atoms of iodine per antibody molecule being introduced.
Claim 8
Dependent Claim
24 words
The method of claim 6, wherein an average of at least 5 atoms of iodine per antibody molecule are introduced by direct chemical substitution.
Claim 9
Dependent Claim
121 words
In a method for determining the location of a tumor which either produces or is associated with carcinoembryonic antigen, which comprises injecting a human subject parenterally with an antibody specific to CEA and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device and subsequently scanning the subject with said device to determine the location of the resultant uptake of said labeled antibody by said tumor; the improvement which comprises using as said anti-CEA antibody a substantially monospecific antibody having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%, said antibody being radiolabeled to an extent sufficient to reduce its CEA-specific immunoreactivity by from 5 to 33%.
Claim 10
Dependent Claim
121 words
In a method for determining the location of a tumor which either produces or is associated with carcinoembryonic antigen, which comprises injecting a human subject parenterally with an antibody specific to CEA and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device and subsequently scanning the subject with said device to determine the location of the resultant uptake of said labeled antibody by said tumor; the improvement which comprises using as said anti-CEA antibody a substantially monospecific antibody having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%, said antibody being radiolabeled to an extent sufficient to reduce its CEA-specific immunoreactivity by from 5 to 33%.
Claim 11
Dependent Claim
15 words
The method of claim 8, wherein said substantially monospecific antibody is a monoclonal anti-CEA antibody.
Claim 12
Dependent Claim
28 words
The method of claim 8, wherein said substantially monospecific antibody has a CEA-specific immunoreactivity prior to labeling of at least 80% and a cross-reactivity of less than 10%.
Claim 13
Dependent Claim
27 words
The method of claim 9, wherein said monoclonal antibody has a CEA-specific immunoreactivity prior to labeling of at least 90% and a cross-reactivity of less than 10%.
Claim 14
Dependent Claim
43 words
The method of claim 8, wherein said substantially monospecific anti-CEA antibody is radiolabeled with one of Iodine-131, Iodine-123, Iodine-126, Iodine-133, Bromine-77, Indium-111, Indium-113m, Gallium-67, Gallium-68, Ruthenium-95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-107, Mercury-203, Rhenium-99m, Rhenium-105, Rhenium-101, Tellurium-121m, Tellurium-122m, Tellurium-125m, Thulium-165, Thulium-167, Thulium-168, Technetium-99m and Fluorine-18.
Claim 15
Dependent Claim
31 words
The method of claim 8, wherein said substantially monospecific anti-CEA antibody is radiolabeled with Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody molecule being introduced.
Claim 16
Dependent Claim
30 words
The method of claim 10, wherein said monoclonal anti-CEA antibody is radiolabeled with Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody molecule being introduced.
Claim 17
Dependent Claim
107 words
The method of claim 8, which further comprises concurrently injecting said subject with normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with a different radioisotope of the same element used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device, the level of activity of the labeled normal immunoglobulin being used to determine the distribution of background activity due to non-targeted specific antibody, said distribution being subtracted from the total activity of specific antibody whereby the activity of substantially only the targeted, tumor-associated antibody is determined.
Claim 18
Dependent Claim
31 words
The method of claim 15, wherein said substantially monospecific antibody is labeled with one of I-131 and I-123, and said normal immunoglobulin is labeled with the other of I-131 and I-123.
Claim 19
Dependent Claim
57 words
Substantially monospecific anti-CEA antibody having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%, said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, the extent of radiolabeling being sufficient to reduce said CEA-specific immunoreactivity by from 5 to 33%.
Claim 20
Dependent Claim
57 words
Substantially monospecific anti-CEA antibody having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%, said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, the extent of radiolabeling being sufficient to reduce said CEA-specific immunoreactivity by from 5 to 33%.
Claim 21
Dependent Claim
43 words
The antibody of claim 17, wherein said substantially monospecific anti-CEA antibody is radiolabeled with one of Iodine-131, Iodine-123, Iodine-126, Iodine-133, Bromine-77, Indium-111, Indium-113m, Gallium-67, Gallium-68, Ruthenium-95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-107, Mercury-203, Rhenium-99m, Rhenium-105, Rhenium-101, Tellurium-121m, Tellurium-122m, Tellurium-125m, Thulium-165, Thulium-167, Thulium-168, Technetium-99m and Fluorine-18.
Claim 22
Dependent Claim
26 words
The antibody of claim 17, wherein said radioisotope is Iodine-131 or Iodine-123, an average of at least 2.5 atoms of iodine per antibody molecule being introduced.
Claim 23
Dependent Claim
20 words
The antibody of claim 17, wherein said CEA-specific immunoreactivity is at least 80% and said cross-reactivity is less than 10%.
Claim 24
Dependent Claim
25 words
The antibody of claim 20, wherein said radioisotope is Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody being introduced.
Claim 25
Dependent Claim
11 words
The antibody of claim 17 which is a monoclonal anti-CEA antibody.
Claim 26
Dependent Claim
25 words
The antibody of claim 22, wherein said radioisotope is Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody being introduced.
Claim 27
Dependent Claim
82 words
An injectable composition which comprises (a) an antibody specific to carcinoembryonic antigen and radiolabeled with a pharmaceutically inert radioisotope capable of detection using a photoscanning device; (b) normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with a different isotope of the same element used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device; and (c) a pharmaceutically acceptable injection vehicle.
Claim 28
Dependent Claim
82 words
An injectable composition which comprises (a) an antibody specific to carcinoembryonic antigen and radiolabeled with a pharmaceutically inert radioisotope capable of detection using a photoscanning device; (b) normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with a different isotope of the same element used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device; and (c) a pharmaceutically acceptable injection vehicle.
Claim 29
Dependent Claim
41 words
The composition of claim 24, wherein the specific anti-CEA antibody is labeled with one of, and the normal immunoglobulin is labeled with the other of Iodine-131 and Iodine-123; Indium-111 and Indium-113m; Gallium-67 and Gallium-68; Ruthenium-97 and Ruthenium-103; or Mercury-197 and Mercury-203.
Claim 30
Dependent Claim
31 words
The composition of claim 24, wherein the specific anti-CEA antibody is labeled with one of Iodine-131 or Iodine-123 and the normal immunoglobulin is labeled with the other of Iodine-131 or Iodine-123.
Claim 31
Dependent Claim
70 words
An injectable composition which comprises (a) substantially monospecific anti-CEA antibody having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%, said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, the extent of radiolabeling being sufficient to reduce said CEA-specific immunoreactivity by from 5 to 33%; and (b) a pharmaceutically acceptable injection vehicle.
Claim 32
Dependent Claim
70 words
An injectable composition which comprises (a) substantially monospecific anti-CEA antibody having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%, said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, the extent of radiolabeling being sufficient to reduce said CEA-specific immunoreactivity by from 5 to 33%; and (b) a pharmaceutically acceptable injection vehicle.
Claim 33
Dependent Claim
20 words
The composition of claim 27, wherein said CEA-specific immunoreactivity is at least 80% and said cross-reactivity is less than 10%.
Claim 34
Dependent Claim
25 words
The composition of claim 28, wherein said radioisotope is Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody being introduced.
Claim 35
Dependent Claim
13 words
The composition of claim 27, wherein said antibody is a monoclonal anti-CEA antibody.
Claim 36
Dependent Claim
25 words
The composition of claim 30, wherein said radioisotope is Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody being introduced.
Claim 37
Independent Claim
74 words
A method of tumor radiotherapy, which comprises parenterally injecting into a human subject having a tumor which produces or is associated with carcinoembryonic antigen (CEA) a tumor-reducing amount of an antibody which is specific to CEA and radiolabeled with a pharmacologically inert, radiotherapeutically effective radioisotope; wherein said antibody is substantially monospecific to CEA, having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%.
Claim 38
Independent Claim
74 words
A method of tumor radiotherapy, which comprises parenterally injecting into a human subject having a tumor which produces or is associated with carcinoembryonic antigen (CEA) a tumor-reducing amount of an antibody which is specific to CEA and radiolabeled with a pharmacologically inert, radiotherapeutically effective radioisotope; wherein said antibody is substantially monospecific to CEA, having a CEA-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to other antigens of less than 15%.
Claim 39
Dependent Claim
13 words
The method of claim 32, wherein said antibody is a monoclonal anti-CEA antibody.
Claim 40
Dependent Claim
21 words
The method of claim 32, wherein said radioisotope is I-131 and said amount is from 25 to 250 mCi per administration.
Claim 41
Dependent Claim
56 words
The composition of claim 27, which further comprises normal immunoglobulin from the same or different species as that used to prepare said specific antibody, said normal immunoglobulin being radiolabeled with a different isotope of the same element used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device.
Claim 42
Independent Claim
115 words
A method of tumor radiotherapy, which comprises the steps of parenterally injecting into a human subject having a tumor which produces or is associated with CEA a radiotherapeutically effective amount of an antibody which is specific to CEA and radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination an addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope; locating said tumor by scanning the subject with said photoscanning device to determine the location of the resultant uptake of said labeled antibody by said tumor; and directing a beam of thermal neutrons at said tumor location.
Claim 43
Independent Claim
115 words
A method of tumor radiotherapy, which comprises the steps of parenterally injecting into a human subject having a tumor which produces or is associated with CEA a radiotherapeutically effective amount of an antibody which is specific to CEA and radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination an addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope; locating said tumor by scanning the subject with said photoscanning device to determine the location of the resultant uptake of said labeled antibody by said tumor; and directing a beam of thermal neutrons at said tumor location.
Claim 44
Dependent Claim
36 words
The injectable composition of claim 24 or 27, wherein said radiolabeled anti-CEA antibody further contains in chemical combination an addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope.
Claim 45
Dependent Claim
50 words
An antibody which is specific to carcinoembryonic antigen, said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination an addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope.
Claim 46
Dependent Claim
50 words
An antibody which is specific to carcinoembryonic antigen, said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination an addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope.
Claim 47
Dependent Claim
32 words
The antibody of claim 17, wherein said radiolabeled antibody further contains in chemical combination an addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-09-06 | 1986-03-08 | 1986-09-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-09-06 | 1990-03-08 | 1990-09-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-09-06 | 1994-03-08 | 1994-09-07 | $7700.00 | Window Closed / Lapsed |